Edited by George M. Carman Phosphatidic acid (PA) and the conserved integral ER membrane protein Scs2p regulate localization of the transcriptional repressor Opi1p, which controls expression of phospholipid biosynthesis genes, but the mechanisms conducting Opi1p localization are not fully understood. A new study suggests the existence of a distinct pool of PA in the ER that is required for regulation of Opi1p localization and thus phospholipid metabolism in yeast.
Phosphatidic acid (PA) and the conserved integral ER membrane protein Scs2p regulate localization of the transcriptional repressor Opi1p, which controls expression of phospholipid biosynthesis genes, but the mechanisms conducting Opi1p localization are not fully understood. A new study suggests the existence of a distinct pool of PA in the ER that is required for regulation of Opi1p localization and thus phospholipid metabolism in yeast.
Phospholipid composition must be tightly regulated throughout the cell in order for phospholipids to carry out their essential roles in establishing membrane structure, modulating activities of membrane proteins, and participating in signal transduction. However, the detailed mechanisms by which phospholipids and their precursors are sensed, how precursors are partitioned among phospholipid biosynthetic pathways, and how sensory and regulatory mechanisms work together remain to be characterized.
Our understanding of how cells coordinately control the complex pathways of phospholipid metabolism in eukaryotes is largely derived from genetic, biochemical, and cell biological studies in the yeast Saccharomyces cerevisiae. Phospholipid synthesis in yeast is regulated in response to the availability of phospholipid precursors inositol and choline by three proteins, Ino2p, Ino4p, and Opi1p, that form what has been termed the Henry regulatory circuit (1, 2) . When inositol is limiting, the Ino2p-Ino4p activator complex binds to the UAS INO sequence in the promoter of INO1 (coding for myo-inositol-3-P synthase, required for the synthesis of inositol), as well as genes encoding phospholipid biosynthetic enzymes, activating their transcription. When inositol is abundant, transcriptional activation is repressed by binding of the negative regulator Opi1p to Ino2p. Opi1p itself is regulated in response to inositol by its cellular localization. It is tethered to the ER during conditions of low inositol through interactions with PA 3 and Scs2p, a conserved ER integral membrane protein (3) . Conversely, elevated inositol availability increases the synthesis of PI from PA, resulting in decreased PA levels and favoring the translocation of Opi1p to the nucleus (3). If inositol and choline are present together, the UAS INO element is further repressed. However, choline by itself does not affect expression of the UAS INO -containing genes. Interestingly, deletion of OPI1, which results in overproduction of inositol, has been shown to decrease synthesis of the mitochondrial phospholipid CL (4); however, regulation of Pgs1p, phosphatidylglycerol-P synthase (which catalyzes the first step in CL synthesis), is not mediated at the level of mRNA abundance in response to inositol and does not require Ino2p-Ino4p/Opi1p (5) . These findings raise the following questions: What is the role of the Opi1p-Scs2p interaction in the regulation of Opi1p translocation? How does choline modulate regulation? How is CL synthesis regulated by Opi1p and inositol if not by transcriptional regulation? The current study by Gaspar et al. (6) uses elegant genetic and cell biological approaches to answer these questions.
To understand the importance of the interaction between Opi1p and Scs2p, the authors constructed an Opi1p mutant strain, OPI1 ffat , in which the Opi1p-Scs2p interaction motif, FFAT, was eliminated from the genomic OPI1 locus. Opi1p and Opi1p ffat were also tagged with GFP at the genomic locus to monitor localization of the protein. Loss of the Opi1p-Scs2p interaction in either the Opi1p ffat mutant or scs2⌬ resulted in a weak Ino Ϫ (inositol auxotrophy) phenotype. INO1 expression was somewhat lower than that observed in wild-type cells when shifted from I ϩ to I Ϫ medium. Under these conditions, Opi1p ffat translocated from the nucleus to distinct cytosolic puncta, shown to be lipid droplets enriched with TAG. However, choline supplementation decreased the formation of TAG, and Opi1p was unable to translocate from the nucleus; thus, INO1 was constitutively repressed, even though PA levels remained high. This effect of choline supplementation was abrogated by genetically blocking the CDP-choline (Kennedy) pathway for PC synthesis. These data suggest that Opi1p is directed by a specific PA pool that may be separate from the PA pool used in de novo phospholipid synthesis. Furthermore, PC synthesis by the Kennedy pathway competes for the same pool of PA, thereby limiting TAG synthesis and Opi1p translocation from the nucleus, which further suggests that choline modulation of repression results from reduced availability of PA required for Opi1p translocation from the nucleus.
A fascinating finding of this study is that ablation of the Opi1p-Scs2p interaction either in the Opi1p ffat mutant or scs2⌬ mutant led to decreased levels of the mitochondrial lipid CL. CL synthesis requires transfer of the precursor PA from its site of synthesis in the ER through the outer mitochondrial
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membrane to the inner mitochondrial membrane where it is used to synthesize an essential CL precursor, CDP-DAG. Combined with the finding that deletion of Opi1p reduces CL levels (4), this suggests that the Opi1p-Scs2p interaction is required for the transfer of PA to the mitochondria. Thus, Opi1p regulates CL synthesis by modulating the availability of the precursor PA, not by transcriptional control. Interestingly, in the presence of choline, wild-type and mutant cells had low CL levels, even when PA levels were high. This suggests that CL is also synthesized from the distinct pool of PA that is used for the Kennedy pathway, Opi1p translocation from the nucleus, and TAG synthesis. A separate pool of PA is used for the synthesis of CDP-DAG, the substrate for the de novo synthesis of the major phospholipids (PI, PS, PE, and PC). Fig. 1 presents a simplified model depicting the interaction of Scs2p and Opi1p and the pathways of utilization of PA in the context of Gaspar et al. (6) . How separate pools of PA are generated and maintained remains an important unanswered question. Much of our knowledge about the regulation of phospholipid synthesis is based on studies in yeast. In mammalian cells, unlike in yeast, inositol supplementation does not affect regulation of inositol synthesis (7, 8) , and mammalian homologs of Opi1p have not been identified. This raises the intriguing question of whether regulatory mechanisms of phospholipid synthesis are conserved. Interestingly, a negative regulator of inositol synthesis, IP6K1, has been characterized in mouse embryonic fibroblasts (9) . IP6K1 codes for inositol hexakisphosphate kinase (10) and is not homologous to Opi1p; however, it exhibits properties similar to Opi1p, including translocation from the cytoplasm to the nucleus and repression of mammalian INO1 transcription. Importantly, both of these properties are dependent on the binding of IP6K1 to PA. Perhaps PA is indeed the "conductor" of the regulatory orchestra, and response to PA is the conserved mechanism whereby phospholipid biosynthesis is regulated. Figure 1 . The Opi1p-Scs2p interaction is required for Opi1p translocation from the nucleus and for PA transport into the mitochondria. Gaspar et al. (6) propose that distinct pools of PA are present in the ER. One pool is associated with de novo synthesis of major phospholipids. A smaller pool is used for CL and DAG synthesis. DAG can either be acylated to TAG or used to synthesize PC via the Kennedy pathway. Exogenous choline competes for DAG through the Kennedy pathway and depletes the smaller pool of PA, which is required for Opi1p translocation from the nucleus, whereupon it binds to Scs2p and PA in the ER membrane. Additionally, the interaction of Opi1p with Scs2p is required for PA transfer to the mitochondria for CL synthesis.
